CONICET | Buscador de Institutos y Recursos Humanos

OBJECTIVES: To estimate the budget impact of adopting the saxagliptin/metformin XR fixed-dose combination, to treat type 2 diabetes (T2DM) in the Social Security System of Argentina, compared to the current standard treatment. METHODS: We used an Excel-based budget impact model assuming coverage for one million people. The time horizon was three years from the perspective of a social security organization in Argentina. T2DM prevalence data was obtained from the national risk factor survey conducted by the Ministry of Health. Only pharmaceutical expenditures of oral antidiabetic agents (OAAs) were analyzed. The cost of OAAs was obtained from the prices list adjusted to co-payments, and expressed in 2012 Argentinean pesos. Asset market-share was taken from the QUALIDIAB Database, market studies and data provided by Bristol Myers Squibb. The analysis reported findings in terms of budget impact, per-member per-month (PMPM) and per-patient per-month (PPPM). Probabilistic Sensitivity Analysis (PSA) was performed using Monte-Carlo simulations (10,000 iterations) and included parameters of demographic characteristics, price and market-shares. RESULTS: The net budget impact estimated that the introduction of saxagliptin/metformin XR was $32,930 for the first year, $58,768 for the second year and $85,584 for the third year. The cumulative net budget impact was $177,282. PMPM was $0.0027, $0.0049 and $0.0071 for the first, second and third year, respectively. PPPM was $0.107, $ 0.198 and $0.299 each year, respectively. The cumulative impact in the total annual budget for OAAs represented an increase of 0.27%. Monte Carlo simulation showed that cumulative budget impact varied from 0.08 to 0.30%. CONCLUSIONS: The introduction of saxagliptin/metformin XR in a social security organization as a treatment option for patients with T2DM, has a minimal budgetary impact.